[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100201442":3},{"organization":4,"outcomesModule":7,"designInfo":17,"detailedDescription":11,"studyPopulation":11,"armGroups":23,"interventions":30,"overallOfficials":35,"centralContacts":39,"locations":45,"responsibleParty":64,"collaborators":11,"id":66,"slug":11,"hasResults":67,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":11,"eligibilityCriteria":71,"healthyVolunteers":67,"sex":72,"minAge":73,"maxAge":11,"enrollmentInfo":74,"targetDuration":11,"studyType":77,"phases":78,"briefSummary":81,"conditions":82,"keywords":11,"overallStatus":48,"whyStopped":11,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":93},{"fullName":5,"class":6},"Affiliated Hospital to Academy of Military Medical Sciences","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":11},[9],{"measure":10,"description":11,"timeFrame":12},"PFS\u002FOS",null,"1 years after DC\u002FCIK treatment",[14],{"measure":15,"description":11,"timeFrame":16},"Number of participants with adverse events","3 days within DC\u002FCIK treatment",{"allocation":18,"interventionModel":19,"interventionModelDescription":11,"primaryPurpose":20,"observationalModel":11,"timePerspective":11,"maskingInfo":21},"NA","SINGLE_GROUP","TREATMENT",{"masking":22,"maskingDescription":11,"whoMasked":11},"NONE",[24],{"label":25,"type":26,"description":27,"interventionNames":28},"Adenovirus-transfected DC + CIK","EXPERIMENTAL","Adenovirus-transfected autologous DCs + CIK cells",[29],"Biological: Adenovirus-transfected DC + CIK",[31],{"type":32,"name":25,"description":33,"armGroupLabels":34,"otherNames":11},"BIOLOGICAL","Adenovirus-transfected autologous DC vaccine plus CIK cells",[25],[36],{"name":37,"affiliation":5,"role":38},"Chen Hu, M.D., Ph.D.","PRINCIPAL_INVESTIGATOR",[40],{"name":41,"role":42,"phone":43,"phoneExt":11,"email":44},"Bin Zhang, M.D., Ph.D.","CONTACT","+86-010-6694-7125","zb307ctc@163.com",[46],{"facility":47,"status":48,"city":49,"state":11,"zip":50,"country":51,"countryCode":52,"cosmosGeoPoint":53,"geoPoint":58,"contacts":59},"Department of Hematopoietic Stem Cell Transplantation","RECRUITING","Beijing","100071","China","CN",{"type":54,"coordinates":55},"Point",[56,57],116.39723,39.9075,{"lat":57,"lon":56},[60],{"name":61,"role":42,"phone":62,"phoneExt":11,"email":63},"Dan ho Wang, M.M.","+86-010-6694-7102","wangdh307@sina.com",{"type":65,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100201442",false,"NCT01898663","DCs Vaccine Combined With Cytokine-induced Killer Cells in Patients With AML","Safety and Therapeutic Efficacy of DCs Vaccine Combined With Cytokine-induced Killer Cells in Patients With AML: a Phase Ⅰ\u002FⅡ Study","Inclusion Criteria:\n\n* Consistent with the diagnosis of AML\n* Age≥18 years at time of consent\n* KPS(Karnofsky Performance Scale) ≥70\n* Patient's written informed consent\n* No steroid therapy within 4 weeks of first DC vaccination\n* Stable disease, complete response and partial response(WHO, RECIST)\n* Predicted survival≥3 months\n\nExclusion Criteria:\n\n* Serious dysfunction of vital organs(heart, liver or kidney)\n* Received organ transplantation\n* Patients with other malignancies or brain metastases\n* History of autoimmune diseases\n* Pregnant and breast-feeding patient\n* Active or chronic infectious diseases\n* History of allergy or hypersensitivity to study product excipients\n* Currently participating in another clinical trial\n* Received chemotherapy, radiotherapy, immune inhibitor (such as corticosteroid) or other immunotherapy (such as vaccine) during prior 4 weeks\n* Unfit for participating in this clinical trial in investigators' opinions","ALL","18 Years",{"count":75,"type":76},30,"ESTIMATED","INTERVENTIONAL",[79,80],"PHASE1","PHASE2","The aim of this Phase Ⅰ\u002FⅡ study is to evaluate the safety and efficacy of dendritic cells (DCs) vaccine combined with cytokine-induced killer (CIK) cells in patients with AML. Experimental recombinant adenovirus-transfected DCs, which engineered to express MUC1 and Survivin are used for DCs-based immunotherapy. Based on the results of our previously performed preclinical study with DCs vaccine combined with CIK cells, the investigators plan to perform the clinical trial.",[83],"High-risk Soft Tissue Sarcoma","2024-06-28",{"date":86,"type":87},"2024-07-01","ACTUAL",{"date":89,"type":11},"2013-06",{"date":91,"type":76},"2024-12-30",{"name":5,"class":6},1]